REBIRTH Mitglieder

Figueiredo, Constanca

Figueiredo, Constanca, PD Dr. rer. nat.

Work Group Leader

REBIRTH Unit Tolerogenic Cell Therapy, Department of Cardiothoracic, Transplantation and Vascular Surgery (HTTG), MHH


Biosketch:

C. Figueiredo (*1979), PhD, is group leader for “Tolerogenic Cell Therapy” and MHH faculty member since 2014. Research of C. Figueiredo focuses on the genetic modification of cells, tissues and solid vascularized organs towards decreasing their immunogenicity to support survival after allogeneic transplantation. In addition, she is interested on the scalable in vitro production of low immunogenic blood cells such as erythrocytes and platelets from iPSC.

Biography / About

Date of Birth:December, 1979
Function:Research Group Leader

Education:

10/1997 – 06/2002Diplom in Biology, University of Coimbra, Portugal
07/2002 – 11/2002Post-graduated studies, University of Minho and University of Coimbra, Portugal
11/2002 – 12/2006PhD programme in Biology and Experimental Medicine. University of Coimbra, Portugal and Hannover Medical School, Germany – PhD Thesis: “Reducing the immunogenicity of cell-based therapeutics”
12/2014Post-doctoral lecturing qualification (Habilitation) “Experimental Transfusion Medicine”

Academic appointments and Research posts:

12/2006 – 10/2008Post-Doc Institute for Transfusion Medicine, Hannover Medical School
Since 11/2008 Senior scientist – Group Leader

Other professional activities:

Member of the International Society for Cell Therapy, European Federation for Immunogenetics, American Society for Histocompatibility and Immunogenetics, German Society for Immunogenetics, German Society for Transfusion Medicine and Immunohematology.
Reviewer for several scientific journals as well as national and international research foundations.

Awards and Prizes:

05/2010Julia Bodmer young scientist Award, European Federation for immunogenetics, Florence, Italy
09/2012Next Generation Award, German Society for Immunogenetic, Cologne, Germany
Several Abstracts and Poster Awards

Furthermore:

Lecturer at the PhD programm for “Regenerative Sciences”, “Molecular Medicine” and Bachelor programm in Biology

Selected Publications:

  1. Borger, A. K., Eicke, D., Wolf, C., Gras, C., Aufderbeck, S., Schulze, K., Engels, L., Eiz-Vesper, B., Schambach, A., Guzman, C. A., Lachmann, N., Moritz, T., Martin, U., Blasczyk, R., and Figueiredo, C. Generation of HLA-universal iPSCs-derived megakaryocytes and platelets for survival under refractoriness conditions. Mol Med. 2016 May 16;22. [Epub ahead of print]
  2. Gras, C., Ratuszny, D., Hadamitzky, C., Zhang, H., Blasczyk, R., and Figueiredo, C. miR-145 Contributes to Hypertrophic Scarring of the Skin by Inducing Myofibroblast Activity. Mol Med. 2015 Apr 9;21:296-304.
  3. Ratuszny, D., Gras, C., Bajor, A., Borger, A. K., Pielen, A., Borgel, M., Framme, C., Blasczyk, R., and Figueiredo, C. miR-145 Is a Promising Therapeutic Target to Prevent Cornea Scarring. Hum Gene Ther. 2015 Oct;26(10):698-707.
  4. Zhang, H., Goudeva, L., Immenschuh, S., Schambach, A., Skokowa, J., Eiz-Vesper, B., Blasczyk, R., and Figueiredo, C. miR-155 is associated with the leukemogenic potential of the class IV granulocyte colony-stimulating factor receptor in CD34(+) progenitor cells. Mol Med. 2015 Apr 9;20:736-46.
  5. Schlahsa, L., Zhang, H., Battermann, A., Verboom, M., Immenschuh, S., Eiz-Vesper, B., Stripecke, R., Engelmann, K., Blasczyk, R., and Figueiredo, C. Semaphorin 3A alters endothelial cell immunogenicity by regulating Class II transactivator activity circuits. Transfusion. 2014 Aug;54(8):1961-70.
  6. Wiegmann, B.*, Figueiredo, C.*, Gras, C., Pflaum, M., Schmeckebier, S., Korossis, S., Haverich, A., and Blasczyk, R. Prevention of rejection of allogeneic endothelial cells in a biohybrid lung by silencing HLA-class I expression. Biomaterials. 2014 Sep;35(28):8123-33.* Equal contribution
  7. Gras, C., Eiz-Vesper, B., Jaimes, Y., Immenschuh, S., Jacobs, R., Witte, T., Blasczyk, R., and Figueiredo, C. Secreted semaphorin 5A activates immune effector cells and is a biomarker for rheumatoid arthritis. Arthritis Rheumatol. 2014 Jun;66(6):1461-71.
  8. Gras, C., Schulze, K., Goudeva, L., Guzman, C. A., Blasczyk, R., and Figueiredo, C. HLA-universal platelet transfusions prevent platelet refractoriness in a mouse model. Hum Gene Ther. 2013 Dec;24(12):1018-28.
  9. Figueiredo, C., Wedekind, D., Muller, T., Vahlsing, S., Horn, P. A., Seltsam, A., and Blasczyk, R. MHC universal cells survive in an allogeneic environment after incompatible transplantation. Biomed Res Int 2013, 796046.
  10. Jaimes, Y., Gras, C., Goudeva, L., Buchholz, S., Eiz-Vesper, B., Seltsam, A., Immenschuh, S., Blasczyk, R., and Figueiredo, C. Semaphorin 7A inhibits platelet production from CD34+ progenitor cells. J Thromb Haemost. 2012 Jun;10(6):1100-8.


[zurück zur Liste]
test
Diese Webseite verwendet Cookies und die Webanalyse-Software Google Analytics. Klicken Sie hier für weitere Informationen zum Datenschutz.
Einverstanden